Highlight
– XmAb18968, a novel bispecific antibody targeting CD38 and CD3, was evaluated in relapsed/refractory AML and T-ALL patients.
– The agent showed a tolerable safety profile with no high-grade cytokine release syndrome or neurotoxicity.
– Preliminary efficacy included MRD-negative complete remissions in AML and substantial disease burden improvements in T-ALL.
– Median overall survival exceeded 8 months in both AML and T-ALL cohorts, suggesting clinical benefit in heavily pretreated populations.
